NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Apixaban for Extended Treatment of Provoked VTE: New NEJM Study Challenges Treatment Paradigm
Clinical Research Professionals/LinkedIn
Nov 26, 2025, 04:51

Apixaban for Extended Treatment of Provoked VTE: New NEJM Study Challenges Treatment Paradigm

Emma P. with Clinical Research Professionals shared a post on LinkedIn:

“Apixaban for Extended Treatment of Provoked Venous Thromboembolism
A recent publication in The New England Journal of Medicine explores the benefits of continuing anticoagulation therapy with apixaban in patients who experienced venous thromboembolism (VTE) due to transient provoking factors like surgery, trauma, or immobility. Traditionally, these patients receive short-term anticoagulation, but this study challenges that paradigm.

Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism

Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber

Apixaban for Extended Treatment of Provoked VTE: New NEJM Study Challenges Treatment Paradigm

* Study Design:
Researchers conducted a randomized, double-blind trial comparing extended apixaban therapy to placebo in patients with provoked VTE who had completed initial anticoagulation. The goal: assess whether continued treatment could prevent recurrence without increasing bleeding risk.

* Key Findings:
• Apixaban reduced recurrent VTE by 82% compared to placebo.
• Major bleeding rates were low and comparable between groups.
• The benefit was consistent across subgroups, including those with persistent risk factors like obesity or cancer history.

* Clinical Implications:
This study suggests that extended apixaban therapy may be appropriate for select patients with provoked VTE, especially when enduring risk factors exist. It calls for a more individualized approach to anticoagulation duration—balancing recurrence risk with bleeding concerns.

* Why It Matters:
VTE remains a leading cause of preventable hospital death. This research could reshape guidelines and improve long-term outcomes for thousands of patients annually.

For clinicians, researchers, and policy-makers: this is a pivotal moment to re-evaluate how we define “provoked” VTE and tailor treatment accordingly.

Clinical and Research Focus
Broader Impact and Engagement.”

Apixaban for Extended Treatment of Provoked VTE: New NEJM Study Challenges Treatment Paradigm

Stay updated with Hemostasis Today.

Anticoagulation Antoine Bejjani Apixaban Arvind K. Pandey Behnood Bikdeli Candrika D Khairani Clinical Research Professionals Darsiya Krishnathasan Emma P Gregory Piazza Health Heather Hogan Hematology Hemostasis Hemostasis Today John Fanikos Junyang Lou Lisa Rosenbaum Mariana Pfeferman Marie Gerhard-Herman Medicine Nicole Porio Piotr Sobieszczyk Ruth H. Morrison Samuel Z. Goldhaber Sina Rashedi The New England Journal of Medicine Umberto Campia venous thromboembolism (VTE) Zhou Lan
NewsFeed